EUVIMEDEUVIMED entdecken
Open Access

FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study

Rong Rong Huang, Chunlai Zuo, Christine E Mona, Adrien Holzgreve, Colm Morrissey, Peter S Nelson, Lauren Brady, Lawrence True, Anthony Sisk, Johannes Czernin, Jeremie Calais, Huihui Ye

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.124.268037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Rong Rong Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California. Hauptthemen laut MEDLINE: Antigens, Surface, Endopeptidases, Glutamate Carboxypeptidase II, Immunohistochemistry. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). However, castration-resistant PCa (CRPC) may lose PSMA expression after systemic therapy. Fibroblast activation protein (FAP), expressed by carcinoma-associated fibroblasts in various cancer types, including PCa, has the potential to be an alternative target. In this study, we evaluated FAP expression in CRPC to assess its potential, using PSMA as a comparison.

Methods

FAP expression was assessed using immunohistochemistry in 116 CRPC tumors: 78 adenocarcinomas, 11 small cell carcinomas, and 27 anaplastic carcinomas. Correlation analysis between manual scoring and automated scoring was performed on 54 whole-slide sections of metastatic CRPC. Paired FAP and PSMA stains were assessed in tissue microarray cores of CRPC (n = 62), consisting of locally advanced CRPC (n = 9) and metastatic CRPC (n = 53). FAP and PSMA positivity was defined by an immunohistochemistry score of at least 10. To explore the correlation of PSMA and FAP inhibitor (FAPi) PET imaging and immunohistochemistry, a preliminary analysis of 4 patients included in a [68Ga]-FAPi-46 imaging trial (NCT04457232) was conducted.

Results

Manual and automated scoring of FAP yielded results with strong correlations. Overall, FAP expression in CRPC was notably lower than PSMA expression (median immunoscores, 14 vs. 72; P < 0.001). Different histologic subtypes of CRPC demonstrated distinct levels of PSMA expression, whereas their FAP expression levels were comparable. Among the 19 PSMA-negative tumors, 11 (58%) exhibited FAP positivity. FAP expression levels in lymph node metastases were significantly lower than those in nonnodal metastases (P = 0.021). Liver metastases showed significant enrichment of tumors with strong FAP expression compared with nonliver lesions (P = 0.016). In the 4 clinical trial patients, the biopsied metastatic lesions showed lower uptake on FAPi PET than on PSMA PET (median SUVmax, 9.6 vs. 14.5), consistent with FAP expression that was lower than PSMA expression in the corresponding tumor biopsy samples (median immunoscores, 30 vs. 160).

Conclusion

Because of the low FAP expression levels in CRPC, the utility of FAPi PET imaging may be limited. Although FAPi PET imaging may be further tested in PSMA-negative CRPC, such as small cell carcinoma, other molecular imaging modalities should be evaluated as alternative choices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceEndopeptidasesGlutamate Carboxypeptidase IIImmunohistochemistryProstatic Neoplasms, Castration-ResistantSerine EndopeptidasesAgedAged, 80 and overHumansMaleMiddle AgedGelatinasesGene Expression Regulation, NeoplasticMembrane ProteinsPilot ProjectsPositron-Emission TomographyTranslational Research, BiomedicalClinical Trials, Phase I as TopicFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

CRPCFAPiPET/CTPSMAfibroblast activation proteinprostate cancer

Substanzen

Antigens, SurfaceEndopeptidasesGelatinasesGlutamate Carboxypeptidase IIMembrane ProteinsSerine EndopeptidasesFibroblast Activation Protein AlphaFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Department of Pathology, Rocky Mountain Regional VA Medical Center, Aurora, Colorado.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Department of Urology, University of Washington, Seattle, Washington.
  • Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington; and.

Förderung

  • NCI NIH HHS

Zitieren

APA

Huang, R. R., Zuo, C., Mona, C. E., Holzgreve, A., Morrissey, C., Nelson, P. S., Brady, L., True, L., Sisk, A., Czernin, J., Calais, J., & Ye, H. (2024). FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268037

Vancouver

Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, et al. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.268037

BibTeX
@article{Huang2024,
  author = {Huang, Rong Rong and Zuo, Chunlai and Mona, Christine E and Holzgreve, Adrien and Morrissey, Colm and Nelson, Peter S and Brady, Lauren and True, Lawrence and Sisk, Anthony and Czernin, Johannes and Calais, Jeremie and Ye, Huihui},
  title = {FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.124.268037}
}
Kostenlos starten →